These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
648 related articles for article (PubMed ID: 27167347)
1. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Hao C; Tian J; Liu H; Li F; Niu H; Zhu B Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143 [TBL] [Abstract][Full Text] [Related]
4. Nivolumab: A Review in Advanced Melanoma. Scott LJ Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912 [TBL] [Abstract][Full Text] [Related]
7. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. Afzal MZ; Mercado RR; Shirai K J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520 [TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. Zhang B; Zhou YL; Chen X; Wang Z; Wang Q; Ju F; Ren S; Xu R; Xue Q; Wu Q Int Immunopharmacol; 2019 Mar; 68():131-136. PubMed ID: 30622030 [TBL] [Abstract][Full Text] [Related]
12. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Buchbinder EI; Desai A Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876 [TBL] [Abstract][Full Text] [Related]
16. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Devji T; Levine O; Neupane B; Beyene J; Xie F JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543 [TBL] [Abstract][Full Text] [Related]
17. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333 [TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914 [TBL] [Abstract][Full Text] [Related]
19. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Loo K; Daud AI Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249 [TBL] [Abstract][Full Text] [Related]